ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Sarepta Therapeutics acquires gene therapy firm Myonexus Therapeutics

by Ryan Cross
March 2, 2019 | APPEARED IN VOLUME 97, ISSUE 9

Sarepta Therapeutics, the firm that sells the muscular dystrophy drug eteplirsen, is solidifying its role in the gene-therapy field by acquiring the small start-up Myonexus Therapeutics for $165 million. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, is developing gene therapies to treat five forms of a rare condition called limb-girdle muscular dystrophy. Sarepta licensed these therapies from Myonexus last May.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment